337 related articles for article (PubMed ID: 7686467)
1. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Ross SR; McTavish D; Faulds D
Drugs; 1993 May; 45(5):737-59. PubMed ID: 7686467
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Adkins JC; Peters DH; Markham A
Drugs; 1997 Jun; 53(6):1005-37. PubMed ID: 9179529
[TBL] [Abstract][Full Text] [Related]
3. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with fludarabine in leukaemia.
Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
Anderson VR; Perry CM
Drugs; 2007; 67(11):1633-55. PubMed ID: 17661532
[TBL] [Abstract][Full Text] [Related]
6. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Johnson SA
Hematol J; 2004; 5 Suppl 1():S50-61. PubMed ID: 15079153
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
8. The role of fludarabine in hematological malignancies.
Wright SJ; Robertson LE; O'Brien S; Plunkett W; Keating MJ
Blood Rev; 1994 Sep; 8(3):125-34. PubMed ID: 7819814
[TBL] [Abstract][Full Text] [Related]
9. Oral fludarabine.
Plosker GL; Figgitt DP
Drugs; 2003; 63(21):2317-23. PubMed ID: 14524733
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma.
Churn M; Clough V
Clin Oncol (R Coll Radiol); 2001; 13(4):273-5. PubMed ID: 11554624
[TBL] [Abstract][Full Text] [Related]
11. New initiatives with fludarabine monophosphate in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
[TBL] [Abstract][Full Text] [Related]
12. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine in the management of malignant lymphomas.
Hiddemann W; Pott-Hoeck C
Drugs; 1994; 47 Suppl 6():50-6. PubMed ID: 7525189
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine: a review.
Hood MA; Finley RS
DICP; 1991 May; 25(5):518-24. PubMed ID: 2068837
[TBL] [Abstract][Full Text] [Related]
16. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
[TBL] [Abstract][Full Text] [Related]
20. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
